Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

Novo Nordisk announced a direct-to-consumer program that allows patients to buy Wegovy out of pocket at a lower cost.

Novo Nordisk said it will offer all doses of Wegovy for $499 a month to patients paying cash, a bid to reach consumers who can’t get the blockbuster drug through insurance.

Eli Lilly is offering vials of its weight-loss drug Zepbound to patients at a discount — but only if they skip their ...

Now, the company is adding the 7.5 mg and 10 mg vials. And on Wednesday the maker of Wegovy, a similar weight-loss drug, announced that it, too, would offer direct-to-consumer discounts for ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

The list price for Wegovy remains at $1,349 for a one-month ... cut the monthly price for lower-dosage vials of Zepbound by $50 for consumers who pay cash via the drugmaker's LillyDirect ...

Novo Nordisk said on Wednesday it would begin selling its weight-loss drug Wegovy at a discounted price of $499 per month to patients paying cash, as it grapples with shifts to the competitive ...

India's obesity crisis is intensifying, with big pharma companies like Eli Lilly and Novo Nordisk competing to introduce ...

Both Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy cost over $1,300 per month ... Eli Lilly reduced the monthly price of lower-dosage vials of Zepbound by $50 for cash-paying consumers ...

US-based Lilly and Danish Novo Nordisk have seen skyrocketing global demand for their innovative weight-loss drugs, with ...